<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02446223</url>
  </required_header>
  <id_info>
    <org_study_id>PICATO-2013-01</org_study_id>
    <nct_id>NCT02446223</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%</brief_title>
  <official_title>A Pilot Prospective Clinical Trial to Evaluate the Efficacy and Safety of Large-Scale, Field-Directed Topical Therapy of Actinic Keratosis of the Chest With Ingenol Mebutate 0.015%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goldman, Butterwick, Fitzpatrick and Groff</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Goldman, Butterwick, Fitzpatrick and Groff</source>
  <brief_summary>
    <textblock>
      Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic&#xD;
      Keratosis of the Chest w/Ingenol Mebutate 0.015%&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open-label study to evaluate the efficacy and safety of ingenol mebutate gel,&#xD;
      0.015% used in topical therapy of actinic keratosis on the chest. Subjects that present with&#xD;
      4 or more actinic keratosis in one continuous 100cm2 area of the chest and meet all&#xD;
      inclusion/exclusion criteria will be enrolled into this study.&#xD;
&#xD;
      Treatment with the investigational product (IP) will be applied for three continuous days.&#xD;
      The investigator will guide application of the IP in-office at Day 0 and the subject will be&#xD;
      instructed to self-administer the IP at Days 1 and 2. Follow-up visits will be scheduled at&#xD;
      Days 1, 3, 10, 17, 24 and 59.&#xD;
&#xD;
      Prior to treatment and at each visit, the investigator will assess the subject's treatment&#xD;
      area for lesion counts and at follow up visits 4, 5, 6 and 7 evaluation of clearance.&#xD;
      Pre-treatment photography will also be collected at baseline and at each follow up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Lesion Count From Baseline to Day 59</measure>
    <time_frame>Day 59</time_frame>
    <description>The primary efficacy endpoint will be complete clearance of all clinically visible AKs and no development of any new AKs on day 59. Lesion clearance will be determined on day 59 (visit 7) by comparing pretreatment lesion count with current lesion count on day 59, with primary efficacy endpoint being clearance of all lesions in treatment field and no growth of new lesions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inggenol Mebutate 0.015%</intervention_name>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female of at least 18 years of age.&#xD;
&#xD;
          2. Subjects willing to comply with study requirements.&#xD;
&#xD;
          3. The presence of four or more clinically typical actinic keratosis within one&#xD;
             contiguous area of the chest that is 100cm2.&#xD;
&#xD;
          4. For female subjects of childbearing potential willing to use an acceptable form of&#xD;
             birth control during the entire course of the study. All systemic birth control&#xD;
             measures must be in consistent use at least 30 days prior to entry into the study.&#xD;
&#xD;
             A female is considered NOT to be of childbearing potential if she is postmenopausal&#xD;
             for at least one (1) year, without a uterus, without both ovaries or has had a&#xD;
             bilateral tubal ligation.&#xD;
&#xD;
             Acceptable methods of birth control are: oral contraceptives, contraceptive&#xD;
             patches/rings/implants Norplant, Depo-Provera, double-barrier methods (e.g. condoms&#xD;
             and spermicide) and abstinence.&#xD;
&#xD;
          5. Subjects willing to refrain from the use of topical products containing alpha-hydroxy&#xD;
             acids, retinoic acid, retinol, salicylic acid, and vitamins C/D (or their derivatives)&#xD;
             in the treatment area 7 Days prior to and during the entire study period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity, prior allergic reaction, or prior chest treatment with ingenol&#xD;
             mebutate gel.&#xD;
&#xD;
          2. Treatment area containing hypertrophic or hyperkeratotic lesions, cutaneous horns or&#xD;
             lesions that had previously not responded to other standard treatments.&#xD;
&#xD;
          3. Presence of any skin condition or disease that might interfere with the diagnosis and&#xD;
             evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis, seborrheic&#xD;
             dermatitis).&#xD;
&#xD;
          4. Subjects receiving ablative laser treatments on their chest must have discontinued the&#xD;
             treatment at least 6 months prior to entering the study.&#xD;
&#xD;
          5. Subjects receiving Intense Pulse Light treatments on their chest must have&#xD;
             discontinued the treatment at least 30 days prior to entering the study.&#xD;
&#xD;
          6. Within 3 months of study entry treatments that may interfere with evaluation of the&#xD;
             treatment area (e.g. other topical therapies for actinic keratosis of the chest,&#xD;
             topical corticosteroids, topical retinoids, ultraviolet B phototherapy, or&#xD;
             immunosuppressive, immunomodulating, or cytotoxic medications) or expected use of any&#xD;
             of the above-mentioned therapies in the treatment area listed during the duration of&#xD;
             the study.&#xD;
&#xD;
          7. Within 3 months of study entry topical treatment in the treatment area for actinic&#xD;
             keratosis including, but not limited to imiquimond, 5- fluorouracil, diclofenac or&#xD;
             liquid nitrogen.&#xD;
&#xD;
          8. Within 6 months of study entry treatments with Poly-L-lactic acid (PLLA; Sculptra&#xD;
             Aesthetic) that may interfere with the evaluation of the treatment area.&#xD;
&#xD;
          9. Within 7 days of study entry use of self-tanners, excessive exposure to sunlight or&#xD;
             artificial UV light (e.g.: use of tanning beds/booths and/or sunbathing) or&#xD;
             expectations of any listed during the time of the study within the treatment area.&#xD;
&#xD;
         10. Any systemic disease that is not yet stabilized for at least six (6) Months prior to&#xD;
             entering study.&#xD;
&#xD;
         11. A significant history or current evidence of a medical, psychological or other&#xD;
             disorder that, in the investigator's opinion, would interfere with the objectives of&#xD;
             the study&#xD;
&#xD;
         12. Pregnant or nursing women or women planning a pregnancy during the study period.&#xD;
&#xD;
         13. Any unhealed skin lesions or wounds within the treatment area.&#xD;
&#xD;
         14. Existence of one (1) or more suspected basal cell carcinoma or squamous cell carcinoma&#xD;
             within the treatment area.&#xD;
&#xD;
         15. Current participation or participation within 30 days prior to the start of this study&#xD;
             in a drug or investigational device research study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchel P Goldman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cosmetic Laser Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cosmetic Laser Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 12, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2015</study_first_posted>
  <results_first_submitted>May 1, 2019</results_first_submitted>
  <results_first_submitted_qc>August 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2019</results_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic Keratosis AKs Chest Pre-Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 17, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT02446223/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Inggenol Mebutate</title>
          <description>Inggenol Mebutate 0.015%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active</title>
          <description>Inggenol Mebutate 0.015%</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.0" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Count</title>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.3" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Lesion Count From Baseline to Day 59</title>
        <description>The primary efficacy endpoint will be complete clearance of all clinically visible AKs and no development of any new AKs on day 59. Lesion clearance will be determined on day 59 (visit 7) by comparing pretreatment lesion count with current lesion count on day 59, with primary efficacy endpoint being clearance of all lesions in treatment field and no growth of new lesions.</description>
        <time_frame>Day 59</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Inggenol Mebutate 0.015%</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lesion Count From Baseline to Day 59</title>
          <description>The primary efficacy endpoint will be complete clearance of all clinically visible AKs and no development of any new AKs on day 59. Lesion clearance will be determined on day 59 (visit 7) by comparing pretreatment lesion count with current lesion count on day 59, with primary efficacy endpoint being clearance of all lesions in treatment field and no growth of new lesions.</description>
          <units>Leasion Count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active</title>
          <description>Inggenol Mebutate 0.015%</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <description>Presence of Redness in treatment area at Day 59 visit</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Coordinator</name_or_title>
      <organization>Cosmetic Laser Dermatology/West Dermatology Research</organization>
      <phone>858 657 1004</phone>
      <email>IGuiha@CLderm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

